Your browser doesn't support javascript.
loading
Arrhythmogenicity of anti-tachycardia pacing in patients with implantable cardioverter defibrillator.
Awad, Sherien Samy; Azeez, Emmanuel Fares; Taha, Mohamed Ossama; El-Naggar, Wael Mohamed; El-Damaty, Ahmed.
Afiliação
  • Awad SS; Egyptian Ministry of Health, Al Kasr Al Aini Street, Old Cairo, 11562, Cairo Governorate, Egypt. doctor_shs@hotmail.com.
  • Azeez EF; Cairo University, Cardiovascular Medicine, Cairo, Egypt.
  • Taha MO; National Heart Institute, Cardiovascular Medicine, Cairo, Egypt.
  • El-Naggar WM; Cairo University, Cardiovascular Medicine, Cairo, Egypt.
  • El-Damaty A; Cairo University, Cardiovascular Medicine, Cairo, Egypt.
Egypt Heart J ; 75(1): 44, 2023 Jun 02.
Article em En | MEDLINE | ID: mdl-37266828
ABSTRACT

BACKGROUND:

Anti-tachycardia pacing therapy (ATP) has shown comparable efficacy to shock therapy in ventricular tachycardia (VT) termination with better quality of life. However, some ATPs may lead to VT acceleration or degeneration to ventricular fibrillation (VF), which will result in more ICD shocks. The aim of this study was to investigate the predictors of VT acceleration by ATP therapy in a real-life patient cohort.

RESULTS:

We retrospectively reviewed 448 monomorphic VT episodes that required ATP therapy in 60 patients with structural heart diseases implanted with ICD or CRTD. The clinical data of the patients and the episodes' details were evaluated. We found that patients with a higher ejection fraction (EF) were more likely to be cardioverted by ATP therapy (P 0.024). VT acceleration was more frequent in patients with lower EF (mean 31.24 ± 4.08) compared with the non-accelerated patients with higher EF (mean 37.00 ± 9.4, P 0.016). The percentage of accelerated episodes was 8.5%. VT episodes with a mean cycle length (CL) < 310 ms are more likely to accelerate (sensitivity 76.3%, specificity 67.7%, PPV value 45%, NPV 86%, and AUC 0.790). There was a statistically significant difference in the accelerated VT episodes as compared to non-accelerated episodes regarding the number of ATP bursts (mean 3.66 ± 2.22 vs. 1.76 ± 1.35, P < 0.001), ramp (23.7% vs. 4.2%, P < 0.001), scanning (55.3% vs. 31.3%, P 0.003) and burst adaptive cycle length (mean 83.55 ± 2.92 vs. 84.64 ± 2.61, P 0.016). In a multivariate analysis, the VT CL, number of ATP bursts and ramp pacing predicted VT acceleration by ATP therapy.

CONCLUSIONS:

Ventricular tachycardia in patients with low LV EF and fast VTs with a CL less than 310 ms were more likely to accelerate with ATP therapy. The number of ATP bursts and the use of ramp had a significant effect on VT acceleration. To avoid VT acceleration by ATP therapy, ramp pacing better be avoided, especially in fast VTs, and lesser number of bursts should be delivered.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Egypt Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Egypt Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Egito